<unk>  has been shown to be effective in two major clinical syndromes: idiopathic thrombocytopenic purpura (ITP) and cirrhosis due to hepatitis C (in which low platelet counts may be a contraindication for interferon treatment). After six weeks of therapy in a phase III trial,<unk>  50 mg/day was associated with a significantly higher response rate than placebo in adult patients with chronic idiopathic thrombocytopenic purpura (ITP).
Eltrombopag
Avatrombopag
Lusutrombopag
Ximelagatran
Hirudin
Tirbanibulin
Anistreplase
Desmoteplase